Yuri Rukazenkov
Oncology R&D
Cambridge, ENG, United Kingdom
Cambridge, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: October 17, 2025
Reply to "High Pharmacokinetic Variability and Unrecognized Limitations in First-Line Osimertinib Plus Chemotherapy for EGFR-Mutated NSCLC".
Journal: Clinical pharmacology and therapeutics
Published: August 27, 2025
Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small Cell Lung Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 02, 2025
A plain language summary of results from the FLAURA2 study: Initial (first-line) osimertinib treatment with or without chemotherapy in patients with untreated EGFR-mutated advanced NSCLC.
Journal: Future oncology (London, England)
Published: February 25, 2025
Population Pharmacokinetics and Exposure-Response Analysis of First-Line Osimertinib Plus Chemotherapy in Patients with EGFR-Mutated Advanced NSCLC.
Journal: Clinical pharmacology and therapeutics
Published: February 05, 2025
Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer.
Journal: Pharmacology research & perspectives
Published: November 28, 2024
EGFR mutation testing across the osimertinib clinical program.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: October 07, 2024
Molecular residual disease analysis of adjuvant osimertinib in resected EGFR-mutated stage IB-IIIA non-small-cell lung cancer.
Journal: Nature medicine
Published: September 09, 2024
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 05, 2024
Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.
Journal: Targeted oncology
Published: January 15, 2024
Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.
Journal: British journal of clinical pharmacology
Published: December 15, 2023
Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC.
Journal: The New England journal of medicine
Published: November 08, 2023
Last Updated: 09/26/2026